Blood Cancer Journal (Sep 2024)
Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
- Marie Hairing Enemark,
- Jonas Klejs Hemmingsen,
- Maja Dam Andersen,
- Trine Engelbrecht Hybel,
- Mads Emil Bjørn,
- Pär Lars Josefsson,
- Lars Møller Pedersen,
- Maja Bech Juul,
- Robert Schou Pedersen,
- Michael Thorsgaard,
- Ida Blok Sillesen,
- Trine Lindhardt Plesner,
- Stephen Jacques Hamilton-Dutoit,
- Paw Jensen,
- Charlotte Madsen,
- Maja Ludvigsen
Affiliations
- Marie Hairing Enemark
- Department of Hematology, Aarhus University Hospital
- Jonas Klejs Hemmingsen
- Department of Hematology, Aarhus University Hospital
- Maja Dam Andersen
- Department of Hematology, Aarhus University Hospital
- Trine Engelbrecht Hybel
- Department of Hematology, Aarhus University Hospital
- Mads Emil Bjørn
- Department of Hematology, Copenhagen University Hospital
- Pär Lars Josefsson
- Department of Hematology, Copenhagen University Hospital
- Lars Møller Pedersen
- Department of Hematology, Zealand University Hospital
- Maja Bech Juul
- Department of Hematology, Odense University Hospital
- Robert Schou Pedersen
- Department of Hematology, Region Hospital Gødstrup
- Michael Thorsgaard
- Department of Hematology, Lillebælt Hospital
- Ida Blok Sillesen
- Department of Hematology, Aarhus University Hospital
- Trine Lindhardt Plesner
- Department of Pathology, Copenhagen University Hospital
- Stephen Jacques Hamilton-Dutoit
- Department of Pathology, Aarhus University Hospital
- Paw Jensen
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital
- Charlotte Madsen
- Department of Hematology, Aarhus University Hospital
- Maja Ludvigsen
- Department of Hematology, Aarhus University Hospital
- DOI
- https://doi.org/10.1038/s41408-024-01150-3
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 4
Abstract
No abstracts available.
